Cardiovascular risk in patients with obstructive sleep apnea

Pathophysiology, epidemiology and management

Miranda Lim, Indira Gurubhagavatula

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Despite rising awareness of its high prevalence, myriad of health consequences andresponsiveness to treatment, obstructive sleep apnea (OSA) still remains underrecognizedand therefore untreated. One consequence of untreated OSA is cardiovasculardisease, which has been attributed to several purported mechanisms: increasedsympathetic drive, oxidative stress, inflammation, vascular endothelial dysfunction, largeintra - thoracic pressure fluctuations, mechanically - mediated vessel wall changes andmetabolic dysregulation. These mechanisms may be the basis for why OSA is morecommon among patients with hypertension, coronary artery disease, arrhythmias andstroke. Indeed, epidemiologic studies have provided evidence that untreated severe OSAconfers increased risk of cardiovascular events, but data are limited by small sample sizesand incomplete control for obesity (the major risk factor for OSA). Data from controlledtrials is scarce, but suggests that hypertension may improve with treatment of OSA,particularly in those with severe disease. The first - line treatment for OSA, continuouspositive airway pressure (CPAP), is safe and effective, and should be offered to patientswith severe OSA to reduce cardiovascular risk, and patients with mild to moderate apneaand known cardiovascular disease. Data from randomized intervention studies is needed to establish whether treatment of mild to moderate OSA improves cardiovascularoutcomes.

Original languageEnglish (US)
Title of host publicationCurrent Advances in Cardiovascular Risk (2 Volume Set)
PublisherNova Science Publishers, Inc.
Pages421-438
Number of pages18
Volume2
ISBN (Print)9781620817575
StatePublished - Dec 1 2012
Externally publishedYes

Fingerprint

Obstructive Sleep Apnea
Epidemiology
Hypertension
Pressure
Therapeutics
Blood Vessels
Cardiac Arrhythmias
Epidemiologic Studies
Coronary Artery Disease
Oxidative Stress
Cardiovascular Diseases
Thorax
Obesity
Inflammation
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lim, M., & Gurubhagavatula, I. (2012). Cardiovascular risk in patients with obstructive sleep apnea: Pathophysiology, epidemiology and management. In Current Advances in Cardiovascular Risk (2 Volume Set) (Vol. 2, pp. 421-438). Nova Science Publishers, Inc..

Cardiovascular risk in patients with obstructive sleep apnea : Pathophysiology, epidemiology and management. / Lim, Miranda; Gurubhagavatula, Indira.

Current Advances in Cardiovascular Risk (2 Volume Set). Vol. 2 Nova Science Publishers, Inc., 2012. p. 421-438.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lim, M & Gurubhagavatula, I 2012, Cardiovascular risk in patients with obstructive sleep apnea: Pathophysiology, epidemiology and management. in Current Advances in Cardiovascular Risk (2 Volume Set). vol. 2, Nova Science Publishers, Inc., pp. 421-438.
Lim M, Gurubhagavatula I. Cardiovascular risk in patients with obstructive sleep apnea: Pathophysiology, epidemiology and management. In Current Advances in Cardiovascular Risk (2 Volume Set). Vol. 2. Nova Science Publishers, Inc. 2012. p. 421-438
Lim, Miranda ; Gurubhagavatula, Indira. / Cardiovascular risk in patients with obstructive sleep apnea : Pathophysiology, epidemiology and management. Current Advances in Cardiovascular Risk (2 Volume Set). Vol. 2 Nova Science Publishers, Inc., 2012. pp. 421-438
@inbook{5dbbf21a18ba486c92da74abbfa7ba3c,
title = "Cardiovascular risk in patients with obstructive sleep apnea: Pathophysiology, epidemiology and management",
abstract = "Despite rising awareness of its high prevalence, myriad of health consequences andresponsiveness to treatment, obstructive sleep apnea (OSA) still remains underrecognizedand therefore untreated. One consequence of untreated OSA is cardiovasculardisease, which has been attributed to several purported mechanisms: increasedsympathetic drive, oxidative stress, inflammation, vascular endothelial dysfunction, largeintra - thoracic pressure fluctuations, mechanically - mediated vessel wall changes andmetabolic dysregulation. These mechanisms may be the basis for why OSA is morecommon among patients with hypertension, coronary artery disease, arrhythmias andstroke. Indeed, epidemiologic studies have provided evidence that untreated severe OSAconfers increased risk of cardiovascular events, but data are limited by small sample sizesand incomplete control for obesity (the major risk factor for OSA). Data from controlledtrials is scarce, but suggests that hypertension may improve with treatment of OSA,particularly in those with severe disease. The first - line treatment for OSA, continuouspositive airway pressure (CPAP), is safe and effective, and should be offered to patientswith severe OSA to reduce cardiovascular risk, and patients with mild to moderate apneaand known cardiovascular disease. Data from randomized intervention studies is needed to establish whether treatment of mild to moderate OSA improves cardiovascularoutcomes.",
author = "Miranda Lim and Indira Gurubhagavatula",
year = "2012",
month = "12",
day = "1",
language = "English (US)",
isbn = "9781620817575",
volume = "2",
pages = "421--438",
booktitle = "Current Advances in Cardiovascular Risk (2 Volume Set)",
publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - Cardiovascular risk in patients with obstructive sleep apnea

T2 - Pathophysiology, epidemiology and management

AU - Lim, Miranda

AU - Gurubhagavatula, Indira

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Despite rising awareness of its high prevalence, myriad of health consequences andresponsiveness to treatment, obstructive sleep apnea (OSA) still remains underrecognizedand therefore untreated. One consequence of untreated OSA is cardiovasculardisease, which has been attributed to several purported mechanisms: increasedsympathetic drive, oxidative stress, inflammation, vascular endothelial dysfunction, largeintra - thoracic pressure fluctuations, mechanically - mediated vessel wall changes andmetabolic dysregulation. These mechanisms may be the basis for why OSA is morecommon among patients with hypertension, coronary artery disease, arrhythmias andstroke. Indeed, epidemiologic studies have provided evidence that untreated severe OSAconfers increased risk of cardiovascular events, but data are limited by small sample sizesand incomplete control for obesity (the major risk factor for OSA). Data from controlledtrials is scarce, but suggests that hypertension may improve with treatment of OSA,particularly in those with severe disease. The first - line treatment for OSA, continuouspositive airway pressure (CPAP), is safe and effective, and should be offered to patientswith severe OSA to reduce cardiovascular risk, and patients with mild to moderate apneaand known cardiovascular disease. Data from randomized intervention studies is needed to establish whether treatment of mild to moderate OSA improves cardiovascularoutcomes.

AB - Despite rising awareness of its high prevalence, myriad of health consequences andresponsiveness to treatment, obstructive sleep apnea (OSA) still remains underrecognizedand therefore untreated. One consequence of untreated OSA is cardiovasculardisease, which has been attributed to several purported mechanisms: increasedsympathetic drive, oxidative stress, inflammation, vascular endothelial dysfunction, largeintra - thoracic pressure fluctuations, mechanically - mediated vessel wall changes andmetabolic dysregulation. These mechanisms may be the basis for why OSA is morecommon among patients with hypertension, coronary artery disease, arrhythmias andstroke. Indeed, epidemiologic studies have provided evidence that untreated severe OSAconfers increased risk of cardiovascular events, but data are limited by small sample sizesand incomplete control for obesity (the major risk factor for OSA). Data from controlledtrials is scarce, but suggests that hypertension may improve with treatment of OSA,particularly in those with severe disease. The first - line treatment for OSA, continuouspositive airway pressure (CPAP), is safe and effective, and should be offered to patientswith severe OSA to reduce cardiovascular risk, and patients with mild to moderate apneaand known cardiovascular disease. Data from randomized intervention studies is needed to establish whether treatment of mild to moderate OSA improves cardiovascularoutcomes.

UR - http://www.scopus.com/inward/record.url?scp=84895328253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895328253&partnerID=8YFLogxK

M3 - Chapter

SN - 9781620817575

VL - 2

SP - 421

EP - 438

BT - Current Advances in Cardiovascular Risk (2 Volume Set)

PB - Nova Science Publishers, Inc.

ER -